{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-203889","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2024-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.004897+00:00","generated_at":"2026-05-31T08:13:12.150295+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aadi halts PRECISION1 trial for TSC1/TSC2 cancers; cuts R&D staff 80%, extends cash runway into 2H 2026","bullets":["PRECISION1 trial halted; IDMC found it unlikely to meet efficacy threshold for accelerated approval; 25 benefiting patients eligible for expanded access.","FYARRO Q2 2024 sales of $6.2M; company will focus on FYARRO commercial business for PEComa.","Workforce reductions: 22 employees (32% total) and 80% of R&D staff; non-recurring charges estimated $2.2-2.5M in Q3 2024.","Cash runway extended into at least 2H 2026; company hired advisory firm for comprehensive strategic review to maximize shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-203889","json":"https://secwatch.observer/filing/0001193125-24-203889.json","markdown":"https://secwatch.observer/filing/0001193125-24-203889.md","text":"https://secwatch.observer/filing/0001193125-24-203889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/0001193125-24-203889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/d859038d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:13:12.150295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56eddc7796892867cb033a81a0d0d978aad41463","claim":"Whitehawk Therapeutics, Inc. announced a restructuring with charges of approximately $2.2 to $2.5 million affecting workforce reduction (22 employees, representing approximately 32% of the Company’s workforce).","evidence_excerpt":"a workforce reduction of 22 employees, representing approximately 32% of the Company’s workforce. The Company estimates that it will incur non-recurring charges of approximately $2.2 to $2.5 million in connection with the workforce reduction, primarily consisting of severance payments, employee benefits contributions and related costs. The Company expects that","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/0001193125-24-203889-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.2 to $2.5 million"},{"label":"Affected area","value":"workforce reduction"},{"label":"Headcount","value":"22 employees, representing approximately 32% of the Company’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}